دورية أكاديمية
أعرض في EDS

Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.

التفاصيل البيبلوغرافية
العنوان: Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
المؤلفون: Chiou FK; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom.; Gastroenterology, Hepatology and Nutrition Service, Paediatric Medicine, KK Women's and Children's Hospital, Singapore., Beath SV; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom., Morland B; Paediatric Oncology, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom., Hartley J; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom., van Mourik I; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom., Abdel-Hady M; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom., Kelly DA; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom., Sharif K; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom., Gupte GL; Liver Unit (including small bowel transplantation), Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom.
المصدر: Transplantation [Transplantation] 2020 Jul; Vol. 104 (7), pp. 1429-1436.
نوع المنشور: Comparative Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0132144 Publication Model: Print Cited Medium: Internet ISSN: 1534-6080 (Electronic) Linking ISSN: 00411337 NLM ISO Abbreviation: Transplantation Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Baltimore, Williams & Wilkins.
مواضيع طبية MeSH: Epstein-Barr Virus Infections/*epidemiology , Immunosuppression Therapy/*adverse effects , Intestine, Small/*transplantation , Liver Transplantation/*adverse effects , Lymphoproliferative Disorders/*epidemiology, Adolescent ; B-Lymphocytes/immunology ; Child ; Child, Preschool ; Epstein-Barr Virus Infections/diagnosis ; Epstein-Barr Virus Infections/immunology ; Epstein-Barr Virus Infections/virology ; Female ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Herpesvirus 4, Human/immunology ; Herpesvirus 4, Human/isolation & purification ; Humans ; Incidence ; Infant ; Kaplan-Meier Estimate ; Lymphoproliferative Disorders/diagnosis ; Lymphoproliferative Disorders/immunology ; Lymphoproliferative Disorders/virology ; Male ; Postoperative Complications ; Retrospective Studies ; Risk Factors ; Severity of Illness Index ; Survival Rate ; T-Lymphocytes, Cytotoxic/immunology ; Transplantation, Homologous/adverse effects
مستخلص: Background: Higher incidence of posttransplant lymphoproliferative disorder (PTLD) is reported in the pediatric small bowel transplant (SBTx) population, which may be associated with more aggressive disease and poorer outcome as compared to liver transplant (LTx) recipients. We aim to compare the characteristics and outcome of PTLD in pediatric SBTx against LTx patients at a single center.
Methods: Retrospective review of pediatric SBTx and LTx patients diagnosed with PTLD from 1989 to 2016 was conducted. Diagnosis of PTLD was biopsy-proven based on World Health Organization histologic criteria. Treatment protocol consisted of reduction of immunosuppression (RIS), rituximab (from 2000), cytotoxic T-lymphocyte (CTL) therapy (available in 1999-2004 and from 2011), and chemotherapy.
Results: Thirty-seven PTLD patients were included following LTx (n = 23, incidence = 2.8%) and SBTx (n = 14, incidence = 14.9%). Monomorphic PTLD made up 64% of SBTx and 43% of LTx cases. RIS alone resulted in remission in 50% of LTx patients but none of the SBTx patients (P = 0.002). Poorer overall remission (57% versus 96%, P = 0.004), 2-year (46% versus 91%, P = 0.003), and 5-year survival rates (39% versus 90%, P = 0.002) were observed in the SBTx group. Risk factors associated with mortality following PTLD were SBTx (odds ratio [OR], 12.00; 95% confidence interval [CI], 2.34-61.45; P = 0.003), monomorphic histology (OR, 10.63; 95% CI, 1.88-60.25; P = 0.008), multisite involvement (OR, 6.38; 95% CI, 1.35-30.14; P = 0.019), and tumor involvement of allograft (OR, 5.33; 95% CI, 1.14-24.90; P = 0.033). Introduction of CTL therapy was associated with improved survival.
Conclusions: Majority of PTLD following pediatric SBTx are of monomorphic subtype and associated with poorer outcome as compared to LTx patients. RIS is inadequate as a single strategy in managing PTLD in SBTx and prompt escalation to rituximab and CTL is recommended.
References: Stanley K, Friehling E, Ranganathan S, et al. Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: a literature review. Pediatr Transplant. 2018; 22:e13211.
Mynarek M, Schober T, Behrends U, et al. Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol. 2013; 2013:814973.
Allen UD, Preiksaitis J; AST Infectious Diseases Community of PracticeEpstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant. 2013; 13Suppl 4107–120.
Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct. 2016; 2:e48.
Schober T, Framke T, Kreipe H, et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation. 2013; 95:240–246.
Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005; 46:191–196.
Montanari F, Radeski D, Seshan V, et al. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. Br J Haematol. 2015; 171:491–500.
Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004; 4:222–230.
Gupte GL, Beath SV, Protheroe S, et al. Improved outcome of referrals for intestinal transplantation in the UK. Arch Dis Child. 2007; 92:147–152.
Martinez Rivera A, Wales PW. Intestinal transplantation in children: current status. Pediatr Surg Int. 2016; 32:529–540.
Swerdlow SH, Webber SA, Chadburn A. Swerdlow SH, Campo E, Lee Harris N., et al. Post-transplant lymphoproliferative disorders. In: WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. 2008Lyon, FranceInternational Agency for Research on Cancer (IARD)343–351.
Westrope C, Rowlands H, Morris K, et al. Fixed dilated pupils and tacrolimus toxicity in paediatric liver transplant patients. Pediatr Transplant. 2011; 15:E96–E99.
Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016; 16:2816–2835.
Ruiz P, Bagni A, Brown R, et al. Histological criteria for the identification of acute cellular rejection in human small bowel allografts: results of the pathology workshop at the VIII International Small Bowel Transplant Symposium. Transplant Proc. 2004; 36:335–337.
Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007; 110:1123–1131.
Nalesnik M, Jaffe R, Reyes J, et al. Posttransplant lymphoproliferative disorders in small bowel allograft recipients. Transplant Proc. 2000; 32:1213.
Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg. 2001; 234:404–16. discussion 416.
Nassif S, Kaufman S, Vahdat S, et al. Clinicopathologic features of post-transplant lymphoproliferative disorders arising after pediatric small bowel transplant. Pediatr Transplant. 2013; 17:765–773.
Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010; 23:350–366.
Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001; 97:1165–1171.
Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a children’s oncology group report. Am J Transplant. 2012; 12:3069–3075.
Ramos E, Hernández F, Andres A, et al. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: incidence, clinical features and outcome. Pediatr Transplant. 2013; 17:472–478.
Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012; 9:510–519.
Chiou FK, Beath SV, Wilkie GM, et al. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children. Pediatr Transplant. 2018; 22:e13133.
Huard G, Schiano TD, Moon J, et al. Severe acute cellular rejection after intestinal transplantation is associated with poor patient and graft survival. Clin Transplant. 2017; 31e12956.
Lacaille F, Irtan S, Dupic L, et al. Twenty-eight years of intestinal transplantation in paris: experience of the oldest European center. Transpl Int. 2017; 30:178–186.
Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002; 236:429–36. discussion 436.
Parker A, Bowles K, Bradley JA, et al.; Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation SocietyManagement of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS guidelines. Br J Haematol. 2010; 149:693–705.
تواريخ الأحداث: Date Created: 20191026 Date Completed: 20201014 Latest Revision: 20211204
رمز التحديث: 20221213
DOI: 10.1097/TP.0000000000003004
PMID: 31651718
قاعدة البيانات: MEDLINE
الوصف
تدمد:1534-6080
DOI:10.1097/TP.0000000000003004